Event Abstract

TRANSCUTANEOUS VAGAL NERVE STIMULATION REDUCES PAIN AND MEDICATION USE IN 53 YEAR OLD WOMAN

  • 1 Carrick Institute of Clinical Neuroscience and Rehabilitation, United States

Background: A 53 year old woman presented with chronic pain of 5 years duration refractory to medication, diet change and supplementation. She has beed diagnosed with Celiac disease, Fibromyalgia and hypothyroidism. At the time of presentation she was taking tramadol 100 mg every 4 hours and fentanyl 25 mcg/hour via patch delivery. Her overall level of physical activity was limited due to pain. Methods: Patient was first treated with one 20 minute session of transcutaneous vagal nerve stimulation (tVNS) in the office. Electrode placement was on the left tragus and palmar surface of the left wrist. Frequency was 25 Hz and intensity was comfortable and non-painful. She then completed 8 more sessions over three weeks. Results: At follow up, three weeks after completing the nine sessions she reported she was able reduce her fentanyl to 12 mcg/hour and reduce her tramadol to 100 mg every 6 to 8 hours. In addition, she was able to be more physically active and was more resilient to psychological stress. Conclusion: The author suggests further investigation into transcutaneous vagal nerve stimulation in the treatment of chronic pain.

Keywords: Neuromodulation, Transcutaneous vagus nerve stimulation, Fibromyalgia, chronic pain and treatment, Celiac Disease

Conference: International Symposium on Clinical Neuroscience: Clinical Neuroscience for Optimization of Human Function, Orlando, United States, 7 Oct - 9 Oct, 2016.

Presentation Type: Poster Presentation

Topic: Abstracts ISCN 2016

Citation: Clark DJ (2016). TRANSCUTANEOUS VAGAL NERVE STIMULATION REDUCES PAIN AND MEDICATION USE IN 53 YEAR OLD WOMAN. Front. Neurol. Conference Abstract: International Symposium on Clinical Neuroscience: Clinical Neuroscience for Optimization of Human Function. doi: 10.3389/conf.fneur.2016.59.00072

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 02 Sep 2016; Published Online: 07 Sep 2016.

* Correspondence: Dr. David J Clark, Carrick Institute of Clinical Neuroscience and Rehabilitation, Cape Canaveral, FL, United States, mail@doctordavidclark.com